share_log

东曜药业(1875.HK)：终止覆盖

Dongyao Pharmaceutical (1875.HK): End of coverage

浦銀國際 ·  Jan 26, 2022 00:00

　　Based on changes in coverage, we will stop research coverage of the following companies starting today, and past ratings and target price information will no longer be valid. Details of the current price (as of January 25, 2022) and the date of publication of the last report, ratings and target prices are as follows:

Dongyao Pharmaceutical (1875.HK)

Last report:

2021-08-16 /1H21 Results: CDMO performed well, TAA013 phase III clinical progress/ “buy” rating/target price of HK$9.5

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment